APA (7th ed.) Citation

Gossec, L., Baraliakos, X., Galloway, J., Oke, V., Sfikakis, P., Rampakakis, E., . . . McInnes, I. B. (2026). Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study. Rheumatology & Therapy, 13(2), 347. https://doi.org/10.1007/s40744-025-00821-2

Chicago Style (17th ed.) Citation

Gossec, Laure, Xenofon Baraliakos, James Galloway, Vilija Oke, Petros Sfikakis, Emmanouil Rampakakis, Mohamed Sharaf, Frederic Lavie, and Iain B. McInnes. "Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study." Rheumatology & Therapy 13, no. 2 (2026): 347. https://doi.org/10.1007/s40744-025-00821-2.

MLA (9th ed.) Citation

Gossec, Laure, et al. "Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study." Rheumatology & Therapy, vol. 13, no. 2, 2026, p. 347, https://doi.org/10.1007/s40744-025-00821-2.